Simone Fishburn 🎗️ (@fishburnsimone) 's Twitter Profile
Simone Fishburn 🎗️

@fishburnsimone

Editor in Chief @BioCentury. Dr, the Ph.D-type. Biotech innovation & breaking barriers, one woman at a time. Views are mine, hope to make them yours too.

ID: 470761555

linkhttp://linkedin.com/in/simonefishburn calendar_today22-01-2012 03:53:19

5,5K Tweet

3,3K Followers

1,1K Following

Simone Fishburn 🎗️ (@fishburnsimone) 's Twitter Profile Photo

AZ’s rise in oncology is probably one of biopharma’s all- time top turnaround stories. In this interview with AstraZeneca oncology head Susan Galbraith, we discuss what they did: biocentury.com/article/652988…

BioCentury (@biocentury) 's Twitter Profile Photo

Greg Verdine, Co-Founder, President & CEO of LifeMine Therapeutics and Professor of Chemistry at Harvard University is joining #BioCenturyGrandRounds to deliver a keynote address: Blowing up the small molecule paradigm. Learn more: loom.ly/yydzbC8

Greg Verdine, Co-Founder, President & CEO of LifeMine Therapeutics and Professor of Chemistry at Harvard University is joining #BioCenturyGrandRounds to deliver a keynote address: Blowing up the small molecule paradigm.

Learn more: loom.ly/yydzbC8
Simone Fishburn 🎗️ (@fishburnsimone) 's Twitter Profile Photo

Calling on translational academics! Do you find it hard to meet #biotech VCs and pharmas? Do you have results and an idea that you'd like to showcase? BioCentury's Grand Rounds conference is designed for you. Sept 9-11, Nashville, TN. Find out more: conferences.biocentury.com/grand-rounds

Calling on translational academics! Do you find it hard to meet #biotech VCs and pharmas? Do you have results and an idea that you'd like to showcase? 
BioCentury's Grand Rounds conference is designed for you. 
Sept 9-11, Nashville, TN. 
Find out more: conferences.biocentury.com/grand-rounds
Jeff Cranmer (@jeff_cranmer) 's Twitter Profile Photo

In an exclusive conversation with BioCentury, Jim Wilson describes how he plans to use newly launched GemmaBio as a vehicle to create a sustainable model for ultrarare disease gene therapies by capitalizing on efficiencies gained from a platform model. biocentury.com/article/653189

David Axelrod (@davidaxelrod) 's Twitter Profile Photo

What a heart-wrenching presentation at the DNC by the parents of Hersh Goldberg-Polin, the young hostage currently being held by Hamas in Gaza. "There is a surplus of agony on all sides of the tragic conflict in the Middle East. In a competition of pain, there are no winners."

What a heart-wrenching presentation at the DNC by the parents of Hersh Goldberg-Polin, the young hostage currently being held by Hamas in Gaza.
"There is a surplus of agony on all sides of the tragic conflict  in the Middle East.  In a competition of pain, there are no winners."
BioCentury (@biocentury) 's Twitter Profile Photo

Introducting BioCentury's Back to School 2024. Editor in Chief Simone Fishburn 🎗️ and colleagues drill down on picking the right target, and ask can industry solve its biggest bottleneck? buff.ly/4gieu9K

Jeffrey Flier (@jflier) 's Twitter Profile Photo

This Harvard student speaks the truth. “Zionist” is not a slur. Harvard University students need to stop using it as one. ⁦The Harvard Crimson⁩ thecrimson.com/article/2024/9…

Regeneron Genetics Center (@regenerondna) 's Twitter Profile Photo

RGC’s Gonçalo Abecasis lent his insights during an enlightening panel discussion at BioCentury Grand Rounds on optimizing data for purpose. He shared that at RGC, “We are big believers that genetic variation leads to good therapies.” #BioCenturyGrandRounds 🧬

RGC’s Gonçalo Abecasis lent his insights during an enlightening panel discussion at <a href="/BioCentury/">BioCentury</a> Grand Rounds on optimizing data for purpose. He shared that at RGC, “We are big believers that genetic variation leads to good therapies.” #BioCenturyGrandRounds 🧬
Regeneron Genetics Center (@regenerondna) 's Twitter Profile Photo

BioCentury We’re inspired by Anil Shanker, Ph.D. in his fireside chat about our joint Together for CHANGE initiative to address data and workforce gaps: "This is a dream project to bring together everyone — all pharma, academic partners are invited to join… First we have to build that trust."

BioCentury (@biocentury) 's Twitter Profile Photo

John Oyler’s long game at BeiGeneGlobal: Owning the process from clinical trials to manufacturing. The oncology company's CEO sits down with BioCentury Editor in Chief Simone Fishburn 🎗️ to talk company building and what's next for BeiGene buff.ly/3MRnLYR

BeOne Medicines (@beonemedicines) 's Twitter Profile Photo

Our Co-Founder, Chairman and CEO, John V. Oyler, recently joined Simone Fishburn 🎗️ on the BioCentury podcast. They delved into BeiGene's corporate global growth and our innovative pipeline. Tune in to the show to discover more: bit.ly/4ez5BH4

Our Co-Founder, Chairman and CEO, <a href="/johnvoyler/">John V. Oyler</a>, recently joined <a href="/FishburnSimone/">Simone Fishburn 🎗️</a> on the <a href="/BioCentury/">BioCentury</a>  podcast. They delved into BeiGene's corporate global growth and our innovative pipeline. Tune in to the show to discover more: bit.ly/4ez5BH4
BioCentury (@biocentury) 's Twitter Profile Photo

The value in mapping genetics to the medical phenome: case studies from Vanderbilt University. Nancy Cox discusses insights from longitudinal EHRs, biobank data, and their value to drug developers: a BioCentury Q&A buff.ly/3ZDWUaA

Simone Fishburn 🎗️ (@fishburnsimone) 's Twitter Profile Photo

I had a fantastic conversation too! John V. Oyler occupies a rare position in biotech of having built a $20B+ company in under 15 years. Some of his lessons, via the podcast (available also on Apple, Spotify and more).

Simone Fishburn 🎗️ (@fishburnsimone) 's Twitter Profile Photo

There's a long-standing discussion about whether research should be hypothesis-driven or hypothesis free. Omics are making unbiased discovery more realistic and industry is opening up to that. But academic incentives aren't aligned. @_Ktktktktk discusses: biocentury.com/article/653701…

Simone Fishburn 🎗️ (@fishburnsimone) 's Twitter Profile Photo

And so, with heavy hearts we enter this Jewish New Year. And with more uncertainty and sadness than we have collectively felt for decades. But still the inevitable hope that this will mark a pivot to better days - wishing those who mark it, a good, healthy and peaceful Shana Tova

Simone Fishburn 🎗️ (@fishburnsimone) 's Twitter Profile Photo

Before I fully go to bluesky, a message for everywhere: VOTE. Vote like it matters, because it does. Get other people to vote. And most of all, take your kids to vote. Not less important than soccer practice, baseball games or Halloween. Vote.

Simone Fishburn 🎗️ (@fishburnsimone) 's Twitter Profile Photo

So often I hear, “my vote doesn’t make a difference- I’m in a blue/red state.” Not true. The Iowa poll shows that. States change when people turn up. Don’t leave your fate - or democracy - to others. Vote.

Simone Fishburn 🎗️ (@fishburnsimone) 's Twitter Profile Photo

Kicking off 2025 by leaving this platform pretty much for good. Come on over and find me at the other place. @fishburnsimone.bsky.social. You can find there my message to biotechs for the new year. Also on Linkedin linkedin.com/in/simonefishb….